CD274 and neoplasm: A subsequent study examining the relationship between the activity of pembrolizumab and PD-L1 expression in the patients enrolled in KEYNOTE-001 trial showed that PD-L1 expression in pretreatment tumor biopsy samples correlated with response rate, PFS, and OS.